FlashFeed

Full text

Spider-Man: Brand New Day brings Tom Holland's Peter Parker back for a new adventure. Set after the harrowing events of No Way Home, the world has forgotten who he is but that doesn't mean the threats have stopped as a new invisible villain is lurking in the shadows.

The latest movie marks the fourth outing for Holland's webslinger, who straddles the world of Sony's Marvel universe and the MCU. However, he's by no means the only Spidey-adjacent character on our screens. There are the Spider-Verse animated movies, Nicolas Cage's variant in Spider-Noir, and there's the Venom, Madame Web, and Morbius movies too.

Speaking in the new issue of SFX magazine , producer Amy Pascal teased that she thinks there are plenty more stories to tell in this universe too, but they have to be justified.

"You don't want to just keep exploiting the same character," Pascal explained. "I think that would make it unspecial for the world. So there are other things in the Spider-Man universe that I think are really fun for us to explore, because the comics were so varied and so creative. I think Peter Parker should exist in live action, and I love what we're doing with Miles in the animated movies. We just have to be really careful that we're being smart about all this."

At the moment, the only other Spider-Man movie that's confirmed is the upcoming third film in the Spider-Verse trilogy, Beyond the Spider-Verse . There are some more animated stories being developed based around Spider-Punk and Spider-Gwen and it's unclear whether Holland will be back again as Parker in the future.

It seems only time – and potentially the events of Brand New Day – will tell what's next with the character on our screens.

Spider-Man: Brand New Day swings into theaters in the UK on July 29 and the US on July 31. For more, check out our guides to all the upcoming Marvel movies and shows on the way, as well as our breakdown of how to watch the Marvel movies in order .

Full text

LONDON — When researchers started planning a pancreatic cancer conference here, the aim was to simply offer a counterpart to a regular U.S. meeting , where international scientists and doctors could discuss the latest developments in the specialty.

Then came the biggest shake-up in pancreatic cancer care in decades.

“It’s one of those moments,” Talia Golan, an oncologist at Israel’s Sheba Medical Center, said on a panel that conference organizers hastily added to the schedule centered on a new pancreatic cancer drug. She likened the medicine’s recent clinical trial performance to other milestones in cancer treatment such as the arrival of the first checkpoint inhibitors.

Continue to STAT+ to read the full story…